Espoo, Finland

Tom Wikberg

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent. Top assignee: Orion-Yhtyma Oy. Active years: 1995-1996.


% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 1995-1996

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Tom Wikberg

Introduction

Tom Wikberg is a notable inventor based in Espoo, Finland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of congestive heart failure. With a total of three patents to his name, Wikberg's work exemplifies the intersection of science and innovation.

Latest Patents

Wikberg's latest patents include a compound known as (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl) phenyl]-hydrazono] propane dinitrile and its salts. This compound is specifically prepared and utilized for treating congestive heart failure. Additionally, he has developed diastereomeric intermediate salts of formulae (IIIa) or (IIIb), which are also significant in his research.

Career Highlights

Wikberg is associated with Orion-yhtyma Oy, a prominent company in the pharmaceutical industry. His work at Orion has allowed him to focus on innovative solutions that address critical health issues. His dedication to research and development has positioned him as a key figure in his field.

Collaborations

Throughout his career, Wikberg has collaborated with esteemed colleagues such as Pentti T. Nore and Erkki J. Honkanen. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Tom Wikberg's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his commitment to improving healthcare solutions. His work continues to inspire advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…